Intuitive Surgical announced strong Q2 2024 results, with revenue increasing 14% to $2.01 billion. Worldwide da Vinci procedures grew 17% year-over-year, while the installed base expanded 14% to 9,203 systems. The company placed 341 da Vinci systems, including 70 new da Vinci 5 models.GAAP net income rose to $527 million, or $1.46 per diluted share, up from $421 million, or $1.18 per share, in Q2 2023. Non-GAAP net income reached $641 million, or $1.78 per diluted share, compared to $507 million, or $1.42 per share, last year. Instruments and accessories revenue grew 16% to $1.24 billion, driven by procedure volume growth.The company ended the quarter with $7.68 billion in cash and investments, an increase of $360 million. Intuitive Surgical noted that the first half of 2024 saw no significant COVID-19 disruptions to procedure volumes, unlike the previous year which experienced some impact in China during Q1 2023.

Intuitive Surgical announced strong Q2 2024 results, with revenue increasing 14% to $2.01 billion. Worldwide da Vinci procedures grew 17% year-over-year, while the installed base expanded 14% to 9,203 systems. The company placed 341 da Vinci systems, including 70 new da Vinci 5 models.GAAP net income rose to $527 million, or $1.46 per diluted share, up from $421 million, or $1.18 per share, in Q2 2023. Non-GAAP net income reached $641 million, or $1.78 per diluted share, compared to $507 million, or $1.42 per share, last year. Instruments and accessories revenue grew 16% to $1.24 billion, driven by procedure volume growth.The company ended the quarter with $7.68 billion in cash and investments, an increase of $360 million. Intuitive Surgical noted that the first half of 2024 saw no significant COVID-19 disruptions to procedure volumes, unlike the previous year which experienced some impact in China during Q1 2023.